Gain Therapeutics (GANX) Research & Development (2020 - 2026)

Gain Therapeutics has reported Research & Development for 7 years, with the latest figure at $2.1 million in Q2 2026.

• On a quarterly basis, Research & Development fell 22.5% year-over-year to $2.1 million in Q2 2026; TTM through Jun 2026 was $10.1 million, a 13.94% increase from a year earlier, with the FY2025 full-year figure at $10.2 million, down 5.36% from the prior year.
• Research & Development was $2.1 million for Q2 2026 at Gain Therapeutics, down from $2.8 million in the prior quarter.
• The five-year high for Research & Development was $4.4 million in Q2 2024, with the low at $1.2 million in Q4 2024.
• Average Research & Development over 5 years is $2.5 million, with a median of $2.4 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development sank 48.41% in 2024, then surged 91.65% in 2025.
• Over 5 years, Research & Development stood at $2.3 million in 2022, then increased by 4.4% to $2.4 million in 2023, then tumbled by 48.41% to $1.2 million in 2024, then surged by 91.65% to $2.3 million in 2025, then fell by 8.91% to $2.1 million in 2026.
• The last three Research & Development figures came in at $2.1 million (Q2 2026), $2.8 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.